Kopran Limited (KOPRAN.NS)
INR 221.0
(2.62%)
INR 221.0
(2.62%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 166.02 Million INR | -7.21% |
| 2022 | 178.91 Million INR | -4.68% |
| 2021 | 187.7 Million INR | -11.51% |
| 2020 | 212.12 Million INR | -33.16% |
| 2019 | 317.37 Million INR | -10.7% |
| 2018 | 355.39 Million INR | 66.53% |
| 2017 | 213.41 Million INR | -30.16% |
| 2016 | 305.58 Million INR | 6.53% |
| 2015 | 286.85 Million INR | 104.82% |
| 2014 | 140.05 Million INR | -77.85% |
| 2013 | 632.26 Million INR | -9.0% |
| 2012 | 694.81 Million INR | 7.58% |
| 2011 | 645.86 Million INR | -34.02% |
| 2010 | 978.85 Million INR | -10.93% |
| 2009 | 1.09 Billion INR | -4.31% |
| 2008 | 1.14 Billion INR | -17.19% |
| 2007 | 1.38 Billion INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 174.83 Million INR | 0.0% |
| 2023 FY | 166.02 Million INR | -7.21% |
| 2023 Q4 | 166.02 Million INR | 0.0% |
| 2022 Q4 | 178.91 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 178.65 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 178.91 Million INR | -4.68% |
| 2021 Q4 | 187.7 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 187.7 Million INR | -11.51% |
| 2021 Q2 | 204.95 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 213.7 Million INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 212.12 Million INR | 0.0% |
| 2020 FY | 212.12 Million INR | -33.16% |
| 2019 Q2 | 321.14 Million INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 317.37 Million INR | -10.7% |
| 2019 Q4 | 317.37 Million INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q4 | 355.39 Million INR | 0.0% |
| 2018 FY | 355.39 Million INR | 66.53% |
| 2018 Q2 | 443.39 Million INR | 0.0% |
| 2017 FY | 213.41 Million INR | -30.16% |
| 2017 Q4 | 299.21 Million INR | 0.0% |
| 2017 Q2 | 276.6 Million INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q3 | - INR | -100.0% |
| 2016 Q4 | 305.58 Million INR | 0.0% |
| 2016 FY | 305.58 Million INR | 6.53% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 357.7 Million INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2015 Q2 | 180.6 Million INR | 0.0% |
| 2015 Q1 | - INR | 0.0% |
| 2015 FY | 286.85 Million INR | 104.82% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q4 | 286.85 Million INR | 0.0% |
| 2014 FY | 140.05 Million INR | -77.85% |
| 2013 Q4 | 632.26 Million INR | 0.0% |
| 2013 FY | 632.26 Million INR | -9.0% |
| 2012 Q4 | 694.81 Million INR | 0.0% |
| 2012 FY | 694.81 Million INR | 7.58% |
| 2012 Q2 | 1.3 Billion INR | 0.0% |
| 2011 FY | 645.86 Million INR | -34.02% |
| 2010 FY | 978.85 Million INR | -10.93% |
| 2009 FY | 1.09 Billion INR | -4.31% |
| 2008 FY | 1.14 Billion INR | -17.19% |
| 2007 FY | 1.38 Billion INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Abbott India Limited | 367.6 Million INR | 54.835% |
| Cipla Limited | 2.25 Billion INR | 92.635% |
| Gland Pharma Limited | 1.06 Billion INR | 84.416% |
| GlaxoSmithKline Pharmaceuticals Limited | 64.69 Million INR | -156.646% |
| Marksans Pharma Limited | 1.9 Billion INR | 91.263% |
| NGL Fine-Chem Limited | 7.44 Million INR | -2129.149% |
| Pfizer Limited | 543.5 Million INR | 69.452% |
| Sanofi India Limited | 139 Million INR | -19.444% |
| SMS Pharmaceuticals Limited | 1.22 Billion INR | 86.401% |
| TTK Healthcare Limited | 7.98 Million INR | -1978.715% |